Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Location: Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States | Website: https://larimartx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
297M
52 Wk Range
$1.61 - $6.91
Previous Close
$3.47
Open
$3.43
Volume
1,012,583
Day Range
$3.36 - $3.74
Enterprise Value
125.9M
Cash
175.4M
Avg Qtr Burn
-24.12M
Insider Ownership
1.07%
Institutional Own.
-
Qtr Updated
09/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |